Immunosuppressive Therapy in Aplastic Anemia
Indian Journal of Hematology and Blood Transfusion · 2026-11 · 42 (6) · 2335-2346
DOI: 10.1007/s12288-026-02522-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 23.07.2026. Verfasst von Mukul Aggarwal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, All India Institute of Medical Sciences, New Delhi, India. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Upon completing this manuscript, readers should be able to: Enlist various historical milestones in the field of IST for AA. Explain the underlying pathophysiology and mechanisms of action of modern IST. Describe the current standard regimens of IST Critically analyze the clinical outcome data from Indian and global cohorts, Recognize the factors influencing variations in efficacy and prognosis of patients receiving IST. Immunosuppressive therapy (IST) has been transformative in the management of aplastic anemia (AA) that is immune-mediated, especially for patients who are ineligible for hematopoietic stem cell transplantation. This manuscript offers a detailed account of IST, covering its historical development, immunological underpinnings, clinical administration and outcomes from both Indian and global cohorts. Evidence indicates that the combination of cyclosporine A (CsA) and anti-thymocyte globulin (ATG), with the addition of thrombopoietin receptor agonist (TPO RA)- eltrombopag (EPAG), yields overall response rates between 60 and 90%. Indian data reveal comparable efficacy to international experience, albeit with unique challenges related to access and long-term monitoring. Ongoing research is focused on novel immunosuppressants, risk stratification using molecular markers, and preventing relapses or clonal evolution.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Manoranjan Mahapatra
Zitieren
APA
Aggarwal, M., & Mahapatra, M. (2026). Immunosuppressive Therapy in Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion, 42(6), 2335-2346. https://doi.org/10.1007/s12288-026-02522-4
Vancouver
Aggarwal M, Mahapatra M. Immunosuppressive Therapy in Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion. 2026;42(6):2335-2346. doi:10.1007/s12288-026-02522-4
BibTeX
@article{Aggarwal2026,
author = {Aggarwal, Mukul and Mahapatra, Manoranjan},
title = {Immunosuppressive Therapy in Aplastic Anemia},
journal = {Indian Journal of Hematology and Blood Transfusion},
year = {2026},
volume = {42},
number = {6},
pages = {2335--2346},
doi = {10.1007/s12288-026-02522-4}
}
EUVIMED